Awakn Life Sciences Completes World’s First Ketamine Study For A Range Of Behavioral Addictions
Collectively, over a billion people struggle with Gambling Disorder, Internet Gaming Disorder, Binge Eating Disorder, and Compulsive Sexual Behaviour.
Researchers at Awakn Life Sciences (AWKN) completed the world’s first ketamine study for these behavioural addictions. The results were “hugely encouraging,” according to the CEO.
While actual data is yet to be released, the promising early findings “merit a larger study and further exploration,” which the company is now pursuing.